Barclays PLC Purchases 5,629 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL)

Barclays PLC grew its stake in shares of Candel Therapeutics, Inc. (NASDAQ:CADL) by 19.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 34,317 shares of the company’s stock after acquiring an additional 5,629 shares during the quarter. Barclays PLC’s holdings in Candel Therapeutics were worth $297,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in CADL. Russell Investments Group Ltd. lifted its position in Candel Therapeutics by 75.1% during the fourth quarter. Russell Investments Group Ltd. now owns 3,753 shares of the company’s stock valued at $33,000 after purchasing an additional 1,610 shares during the period. Wells Fargo & Company MN grew its holdings in Candel Therapeutics by 63.6% during the 4th quarter. Wells Fargo & Company MN now owns 10,122 shares of the company’s stock valued at $88,000 after buying an additional 3,935 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of Candel Therapeutics by 15.2% during the fourth quarter. JPMorgan Chase & Co. now owns 10,426 shares of the company’s stock valued at $90,000 after purchasing an additional 1,375 shares in the last quarter. LPL Financial LLC bought a new position in shares of Candel Therapeutics during the 4th quarter valued at approximately $93,000. Finally, Rhumbline Advisers raised its position in Candel Therapeutics by 17.0% during the fourth quarter. Rhumbline Advisers now owns 26,272 shares of the company’s stock valued at $228,000 after purchasing an additional 3,817 shares during the period. Institutional investors own 13.93% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Canaccord Genuity Group raised their price objective on shares of Candel Therapeutics from $20.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, February 26th. HC Wainwright reiterated a “buy” rating and issued a $19.00 target price on shares of Candel Therapeutics in a research note on Friday, April 11th. Bank of America assumed coverage on Candel Therapeutics in a research note on Friday, February 7th. They set a “buy” rating and a $15.00 price target on the stock. Finally, Citigroup started coverage on Candel Therapeutics in a research note on Thursday, February 20th. They issued a “buy” rating and a $25.00 price objective for the company.

Insider Buying and Selling

In related news, insider Charles Schoch sold 5,000 shares of Candel Therapeutics stock in a transaction on Monday, March 17th. The stock was sold at an average price of $8.83, for a total value of $44,150.00. Following the completion of the transaction, the insider now directly owns 38,038 shares in the company, valued at approximately $335,875.54. This trade represents a 11.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CTO Seshu Tyagarajan sold 31,278 shares of the firm’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $8.82, for a total transaction of $275,871.96. Following the completion of the sale, the chief technology officer now owns 85,512 shares in the company, valued at $754,215.84. The trade was a 26.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. 41.60% of the stock is currently owned by company insiders.

Candel Therapeutics Stock Performance

Shares of Candel Therapeutics stock opened at $4.80 on Monday. Candel Therapeutics, Inc. has a fifty-two week low of $3.79 and a fifty-two week high of $14.60. The firm has a 50-day simple moving average of $6.04 and a two-hundred day simple moving average of $6.68. The company has a market cap of $236.50 million, a P/E ratio of -2.77 and a beta of -0.92.

Candel Therapeutics (NASDAQ:CADL) last posted its quarterly earnings data on Thursday, March 13th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.17). Equities research analysts forecast that Candel Therapeutics, Inc. will post -1.47 EPS for the current year.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.